Department of Pharmacy, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
Int J Mol Sci. 2020 Apr 3;21(7):2491. doi: 10.3390/ijms21072491.
Patients on dialysis are frequently administered high doses of potassium binders such as calcium polystyrene sulfonate (CPS) and sodium polystyrene sulfonate (SPS), which exacerbate constipation. Here, we compare the degree of constipation induced by CPS and SPS using a loperamide-induced constipation model to identify the safer potassium binder. Constipation model was created by twice-daily intraperitoneal administration (ip) of loperamide hydrochloride (Lop; 1 mg/kg body weight) in rats for 3 days. Rats were assigned to a control group, Lop group, Lop + CPS group or Lop + SPS group, and a crossover comparative study was performed. Defecation status (number of feces, feces wet weight, fecal water content and gastrointestinal transit time (GTT)) was evaluated. In the Lop + CPS group, GTT was significantly longer, and fecal water content was reduced. In the Lop + SPS group-although the fecal water content and GTT were unaffected-the number of fecal pellets and the fecal wet weight improved. Thus, SPS was less likely to cause constipation exacerbation than CPS. Considering the high frequency of constipation in dialysis patients with hyperkalemia, preferentially administering SPS over CPS may prevent constipation exacerbation.
透析患者常需服用高剂量的钾结合剂，如聚苯乙烯磺酸钙（CPS）和聚苯乙烯磺酸纳（SPS），这会加重便秘。在这里，我们使用洛哌丁胺诱导的便秘模型比较了 CPS 和 SPS 引起便秘的程度，以确定更安全的钾结合剂。通过在大鼠中每天两次腹腔内给予盐酸洛哌丁胺（Lop；1mg/kg 体重）3 天来创建便秘模型。将大鼠分为对照组、Lop 组、Lop+CPS 组或 Lop+SPS 组，并进行交叉比较研究。评估了排便状态（粪便数量、粪便湿重、粪便含水量和胃肠道转运时间（GTT））。在 Lop+CPS 组中，GTT 明显延长，粪便含水量降低。在 Lop+SPS 组中-尽管粪便含水量和 GTT 不受影响-粪便颗粒的数量和粪便湿重得到改善。因此，SPS 引起便秘恶化的可能性低于 CPS。考虑到高钾血症透析患者便秘的高频率，优先给予 SPS 而不是 CPS 可能预防便秘恶化。
